NasdaqCM:DVAX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor stimulation.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Dynavax Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DVAX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-21.4%

DVAX

-2.8%

US Biotechs

-0.04%

US Market


1 Year Return

101.7%

DVAX

30.6%

US Biotechs

17.1%

US Market

Return vs Industry: DVAX exceeded the US Biotechs industry which returned 31% over the past year.

Return vs Market: DVAX exceeded the US Market which returned 16.8% over the past year.


Shareholder returns

DVAXIndustryMarket
7 Day-21.4%-2.8%-0.04%
30 Day-18.2%-4.1%5.1%
90 Day88.8%4.6%19.5%
1 Year101.7%101.7%32.7%30.6%19.6%17.1%
3 Year-56.3%-56.3%31.0%24.8%42.5%33.3%
5 Year-76.2%-76.2%4.5%-2.9%75.1%56.2%

Price Volatility Vs. Market

How volatile is Dynavax Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DVAX ($7.08) is trading below our estimate of fair value ($33.09)

Significantly Below Fair Value: DVAX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DVAX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DVAX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVAX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVAX is overvalued based on its PB Ratio (13.3x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

52.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVAX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DVAX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DVAX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DVAX's revenue (45.8% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: DVAX's revenue (45.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dynavax Technologies performed over the past 5 years?

-9.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVAX is currently unprofitable.

Growing Profit Margin: DVAX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DVAX is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.

Accelerating Growth: Unable to compare DVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.3%).


Return on Equity

High ROE: DVAX has a negative Return on Equity (-230.53%), as it is currently unprofitable.


Next Steps

Financial Health

How is Dynavax Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DVAX's short term assets ($265.5M) exceed its short term liabilities ($53.2M).

Long Term Liabilities: DVAX's short term assets ($265.5M) exceed its long term liabilities ($217.8M).


Debt to Equity History and Analysis

Debt Level: DVAX's debt to equity ratio (308.2%) is considered high.

Reducing Debt: DVAX's debt to equity ratio has increased from 11.9% to 308.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DVAX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DVAX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DVAX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Ryan Spencer (42 yo)

0.67

Tenure

US$3,157,482

Compensation

Mr. Ryan Spencer serves as the Chief Executive Officer & Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologies ...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD3.16M) is about average for companies of similar size in the US market ($USD2.99M).

Compensation vs Earnings: Insufficient data to compare Ryan's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Ryan Spencer
CEO & Director0.67yrUS$3.16m0.052%
$ 400.3k
David Novack
President & COO0.67yrUS$2.67m0.12%
$ 937.4k
Michael Ostrach
CFO, Chief Business Officer & Senior VP5.42yrsUS$1.50m0.11%
$ 829.5k
Robert Janssen
Chief Medical Officer & Senior VP of Clinical Development7.08yrsUS$1.66m0.12%
$ 901.0k
Justin Burgess
Principal Accounting Officer & Controller0.25yrno datano data
Heather Rowe
Vice President of Investor Relations & Corporate Communications1.58yrsno datano data
Steven Gersten
Chief Ethics & Compliance Officer5.58yrsno datano data
Donn Casale
Vice President of Sales & Marketingno datano datano data
Cecilia Vitug
Vice President of Human Resources13.83yrsno datano data
Jeff Coon
Senior Vice President of Human Resources & Corporate Services1.58yrsno datano data
Cristiana Guiducci
Director & Research Fellowno datano datano data
Nicole Arndt
Senior Manager of Investor Relationsno datano datano data

1.6yrs

Average Tenure

58yo

Average Age

Experienced Management: DVAX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ryan Spencer
CEO & Director0.67yrUS$3.16m0.052%
$ 400.3k
Peggy Phillips
Independent Director14yrsUS$114.64k0.028%
$ 215.7k
Daniel Kisner
Independent Director10.08yrsUS$106.64k0.0014%
$ 10.6k
Arnold Oronsky
Independent Director23.75yrsUS$124.64k0.034%
$ 265.6k
Francis Cano
Independent Director10.75yrsUS$101.64k0.015%
$ 118.0k
Natale Ricciardi
Independent Director7.17yrsUS$94.64kno data
Drew Pardoll
Member of Scientific Advisory Board2.17yrsno datano data
Stanley Plotkin
Member of Scientific Advisory Board2.17yrsUS$20.00kno data
Andrew A. Hack
Independent Interim Chairperson of the Boardno dataUS$55.97kno data
Miriam Merad
Member of Scientific Advisory Board2.17yrsno datano data
Laura Q. Chow
Member of Scientific Advisory Board2.17yrsno datano data
E. Wherry
Member of Scientific Advisory Board2.17yrsno datano data

2.2yrs

Average Tenure

72yo

Average Age

Experienced Board: DVAX's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.9%.


Top Shareholders

Company Information

Dynavax Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DVAX
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$775.342m
  • Shares outstanding: 109.51m
  • Website: https://www.dynavax.com

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2100 Powell Street
  • Suite 900
  • EmeryVille
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DVAXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2004
DYF1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2004
0IDALSE (London Stock Exchange)YesCommon StockGBUSDFeb 2004

Biography

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor stimulation. The company markets ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/11 23:34
End of Day Share Price2020/08/11 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.